2004 NEWS RELEASES
December 22, 2004 HUMAN GENOME SCIENCES ANNOUNCES AGREEMENT TO EXIT FACILITY AT 9800 MEDICAL CENTER DRIVE
November 30, 2004HUMAN GENOME SCIENCES COMPLETES PATIENT ENROLLMENT IN A PHASE 2 CLINICAL TRIAL OF HGS-ETR1 FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER
November 30, 2004HUMAN GENOME SCIENCES INITIATES PHASE 2 CLINICAL TRIAL OF ALBUFERON IN COMBINATION WITH RIBAVIRIN IN TREATMENT-EXPERIENCED HEPATITIS C PATIENTS
November 22, 2004 H. THOMAS WATKINS APPOINTED CHIEF EXECUTIVE OFFICER OF HUMAN GENOME SCIENCES
November 8, 2004 HUMAN GENOME SCIENCES INVITES INVESTORS TO LISTEN TO WEBCAST OF PRESENTATION AT CIBC WORLD MARKETS INVESTMENT CONFERENCE
November 2, 2004HUMAN GENOME SCIENCES REPORTS POSITIVE RESULTS OF PHASE 1/2 CLINICAL TRIAL OF ALBUFERON® IN CHRONIC HEPATITIS C
November 2, 2004 HUMAN GENOME SCIENCES CHARACTERIZES PANEL OF NOVEL HUMAN MONOCLONAL ANTIBODIES THAT SPECIFICALLY ANTAGONIZE THE CCR5 RECEPTOR AND BLOCK HIV-1 ENTRY
November 2, 2004 HUMAN GENOME SCIENCES REPORTS RESULTS OF PRECLINICAL STUDIES OF HGS-TR2J (TRAIL-R2 MAB) AND TRAIL-R2 PROTEIN EXPRESSION
October 26, 2004 HUMAN GENOME SCIENCES ANNOUNCES THIRD QUARTER 2004 FINANCIAL RESULTS
October 26, 2004HUMAN GENOME SCIENCES ANNOUNCES AGREEMENT WITH GLAXOSMITHKLINE FOR DEVELOPMENT AND COMMERCIALIZATION OF NOVEL DRUG TO TREAT DIABETES
October 19, 2004 HUMAN GENOME SCIENCES ANNOUNCES COMPLETION OF REPURCHASE OF CONVERTIBLE SUBORDINATED NOTES
October 13, 2004 HUMAN GENOME SCIENCES BEGINS DOSING OF PATIENTS IN A PHASE 2 CLINICAL TRIAL OF HGS-ETR1 IN NON-HODGKIN'S LYMPHOMA
October 13, 2004 HUMAN GENOME SCIENCES INITIATES A PHASE 2 CLINICAL TRIAL OF HGS-ETR1 IN PATIENTS WITH COLORECTAL CANCER
October 4, 2004 HUMAN GENOME SCIENCES ANNOUNCES COMPLETION OF OFFERING
October 1, 2004 HUMAN GENOME SCIENCES REPORTS RESULTS OF PRECLINICAL STUDIES OF TRAIL-R1 AND TRAIL-R2 AGONISTIC HUMAN MONOCLONAL ANTIBODIES AT EORTC-NCI-AACR SYMPOSIUM
September 29, 2004 HUMAN GENOME SCIENCES REPORTS RESULTS OF ONGOING PHASE 1 CLINICAL TRIALS OF HGS-ETR1 IN PATIENTS WITH ADVANCED CANCERS
September 29, 2004 HUMAN GENOME SCIENCES REPORTS INITIAL RESULTS OF PHASE 1 CLINICAL TRIALS OF HGS-ETR2 (TRAIL-R2 MAB) IN PATIENTS WITH ADVANCED CANCERS
September 29, 2004 HUMAN GENOME SCIENCES ANNOUNCES PRICING OF $250 MILLION PRIVATE PLACEMENT OF CONVERTIBLE SUBORDINATED NOTES
September 27, 2004HUMAN GENOME SCIENCES ANNOUNCES PROPOSED PRIVATE OFFERING OF CONVERTIBLE SUBORDINATED NOTES
September 27, 2004HUMAN GENOME SCIENCES INVITES INVESTORS TO LISTEN TO WEBCAST OF PRESENTATION AT UBS CONFERENCE
September 20, 2004ARGERIS (JERRY) N. KARABELAS, PH.D., TO BECOME CHAIRMAN OF HUMAN GENOME SCIENCES BOARD; CRAIG A. ROSEN, PH.D., NAMED PRESIDENT AND CHIEF OPERATING OFFICER
September 15, 2004HUMAN GENOME SCIENCES INVITES INVESTORS TO LISTEN TO WEBCAST OF PRESENTATION AT BANC OF AMERICA CONFERENCE
September 8, 2004HUMAN GENOME SCIENCES ADVANCES ANTI-CANCER DRUG TO PHASE 2 CLINICAL DEVELOPMENT
September 7, 2004HUMAN GENOME SCIENCES INVITES INVESTORS TO LISTEN TO WEBCAST OF PRESENTATION AT BIOCENTURY/THOMSON FINANCIAL CONFERENCE
August 24, 2004HUMAN GENOME SCIENCES INITIATES CLINICAL DEVELOPMENT OF NEW DRUG FOR THE TREATMENT OF CANCER
July 30, 2004HUMAN GENOME SCIENCES REPORTS SECOND QUARTER 2004 FINANCIAL RESULTS
July 29, 2004HUMAN GENOME SCIENCES COMPLETES PATIENT ENROLLMENT IN A PHASE 2 CLINICAL TRIAL OF LYMPHOSTAT-B FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
July 29, 2004HUMAN GENOME SCIENCES COMPLETES PATIENT ENROLLMENT IN A PHASE 2 CLINICAL TRIAL OF LYMPHOSTAT-B FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS
July 27, 2004HUMAN GENOME SCIENCES INVITES INVESTORS TO LISTEN TO WEBCAST OF PRESENTATION AT BANC OF AMERICA CONFERENCE
June 7, 2004HUMAN GENOME SCIENCES REPORTS RESULTS OF PHASE 1 CLINICAL TRIALS OF HGS-ETR1 (TRAIL-R1 MAB) IN PATIENTS WITH ADVANCED CANCERS
June 3, 2004HUMAN GENOME SCIENCES INVITES INVESTORS TO LISTEN TO WEBCAST OF PRESENTATION AT GOLDMAN SACHS CONFERENCE
May 26, 2004HUMAN GENOME SCIENCES INITIATES PHASE 2 CLINICAL TRIAL OF ALBUFERON FOR THE TREATMENT OF CHRONIC HEPATITIS C
April 30, 2004HUMAN GENOME SCIENCES INVITES INVESTORS TO LISTEN TO WEBCAST OF PRESENTATION AT ROBERT W. BAIRD CONFERENCE
April 28, 2004HUMAN GENOME SCIENCES REPORTS FINANCIAL RESULTS FOR FIRST QUARTER OF 2004
April 23, 2004HUMAN GENOME SCIENCES INVITES INVESTORS TO LISTEN TO WEBCAST OF PRESENTATION AT CIBC WORLD MARKETS CONFERENCE
March 31, 2004HUMAN GENOME SCIENCES ANNOUNCES LICENSE AGREEMENT WITH DAKOCYTOMATION FOR DEVELOPMENT OF PHARMACOGENOMIC DIAGNOSTIC ASSAYS
March 30, 2004HUMAN GENOME SCIENCES RECEIVES MILESTONE PAYMENT FROM GLAXOSMITHKLINE FOR INITIATION OF CLINICAL TRIALS OF GENOMICS-DERIVED DRUG FOR CARDIOVASCULAR DISEASE
March 25, 2004HUMAN GENOME SCIENCES TO SHARPEN FOCUS - ANNOUNCES PLANS TO CONCENTRATE ON DRUGS OF HIGHEST POTENTIAL
March 25, 2004WILLIAM HASELTINE PLANS TO RETIRE AS CHAIRMAN AND CHIEF EXECUTIVE OFFICER OF HUMAN GENOME SCIENCES
March 9, 2004HUMAN GENOME SCIENCES REPORTS RESULTS OF PHASE 1 CLINICAL TRIAL OF ABTHRAX FOR USE IN PREVENTION AND TREATMENT OF ANTHRAX INFECTION
March 5, 2004HUMAN GENOME SCIENCES INVITES INVESTORS TO LISTEN TO WEBCAST OF PRESENTATIONS AT SG COWEN CONFERENCE
March 5, 2004HUMAN GENOME SCIENCES INVITES INVESTORS TO LISTEN TO WEBCAST OF PRESENTATION AT JMP SECURITIES CONFERENCE
March 4, 2004HUMAN GENOME SCIENCES ANNOUNCES SELECTION OF LYMPHOSTAT-BTM FOR PARTICIPATION IN FDA'S CONTINUOUS MARKETING APPLICATION PILOT 2 PROGRAM
March 3, 2004HUMAN GENOME SCIENCES APPOINTS NEW MEMBERS TO ITS BOARD OF DIRECTORS
February 27, 2004 HUMAN GENOME SCIENCES INVITES INVESTORS TO LISTEN TO WEBCAST OF PRESENTATION AT LEHMAN BROTHERS CONFERENCE
February 20, 2004HUMAN GENOME SCIENCES TO PARTICIPATE IN BIO CEO + INVESTOR 2004 CONFERENCE
February 17, 2004HUMAN GENOME SCIENCES CONFIRMS STOCK SALE AND TRANSFER BY CHAIRMAN AND CEO
February 17, 2004HUMAN GENOME SCIENCES AWARDED 'WORKPLACE EXCELLENCE' SEAL OF APPROVAL BY MARYLAND WORK-LIFE ALLIANCE
February 10, 2004HUMAN GENOME SCIENCES REPORTS FINANCIAL RESULTS FOR FULL YEAR AND FOURTH QUARTER 2003
February 5, 2004HUMAN GENOME SCIENCES TO SPONSOR CONFERENCE CALL TO DISCUSS FULL YEAR AND FOURTH QUARTER 2003 FINANCIAL RESULTS
February 2, 2004HUMAN GENOME SCIENCES REPORTS RESULTS OF PHASE 2 CLINICAL TRIAL OF REPIFERMIN IN PATIENTS WITH CANCER THERAPY-INDUCED MUCOSITIS
January 23, 2004HUMAN GENOME SCIENCES INVITES INVESTORS TO LISTEN TO WEBCAST OF PRESENTATION AT PIPER JAFFRAY CONFERENCE
January 12, 2004HUMAN GENOME SCIENCES UPDATES PROGRESS OF SIX DRUGS IN CLINICAL TRIALS AT JPMORGAN CONFERENCE
January 9, 2004HUMAN GENOME SCIENCES INVITES INVESTORS TO LISTEN TO WEBCAST OF PRESENTATION AT JPMORGAN CONFERENCE
January 8, 2004HUMAN GENOME SCIENCES INITIATES PHASE 2 CLINICAL TRIAL OF LYMPHOSTAT-B FOR THE TREATMENT OF RHEUMATOID ARTHRITIS